Program
camtarkibart
Also written as “611”, “Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)” and “611 300 mg Q2W”.
Its studies are mostly in Dermatitis, Atopic · Sinusitis · Pulmonary Disease, Chronic Obstructive, led by 3SBio.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| 3SBio | 115 open or running | phase 3since Dec 7, 2023 | Jul 16, 2020 | Sep 2027phase 3 · NCT07767253 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 16, 2020First study: phase 1 study in HealthyFirst studyNCT04527718 · 40 enrolled · United States
- Sep 9, 2022Phase 2 study in Dermatitis, AtopicNCT05544591 · 93 enrolled · China
- Nov 2, 2022Phase 2 study in Dermatitis, AtopicNCT05641558 · 24 enrolled · China
- Apr 25, 2023Phase 2 study in SinusitisNCT05865496 · 90 enrolled · China
- Oct 19, 2023Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06099652 · 142 enrolled · China
- Dec 7, 2023Phase 3 study in Dermatitis, AtopicNCT06173284 · 519 enrolled · China
- Mar 14, 2024Phase 2 study in Dermatitis, AtopicNCT06324812 · 128 enrolled · China
- Oct 9, 2024Phase 3 study in SinusitisNCT06639295 · 243 enrolled · China
- Jun 5, 20252 phase 3 studiesNCT07039669, NCT07042126
- Aug 7, 2026Phase 3 study in Dermatitis, AtopicNCT07767253 · 246 planned · China
Ahead
- Sep 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT07767253
- Sep 2028Primary completion: phase 3 study in Lung DiseasesNCT07039669
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07767253Dermatitis, Atopic · China | 3 | Recruiting | Sep 2027 | 246 |
| NCT07042126Dermatitis, Atopic · China | 3 | Recruiting | Jun 30, 2026 | 180 |
| NCT07039669Lung Diseases · China | 3 | Recruiting | Sep 2028 | 594 |
| NCT06639295Sinusitis · China | 3 | Active, not recruiting | Dec 2025 | 243 |
| NCT06324812Dermatitis, Atopic · China | 2 | Completed | May 25, 2026 | 128 |
| NCT06173284Dermatitis, Atopic · China | 3 | Completed | Sep 26, 2025 | 519 |
| NCT06099652Pulmonary Disease, Chronic Obstructive · China | 2 | Completed | Apr 15, 2025 | 142 |
| NCT05865496Sinusitis · China | 2 | Active, not recruiting | May 31, 2024 | 90 |
| NCT05641558Dermatitis, Atopic · China | 2 | Completed | Oct 21, 2022 | 24 |
| NCT05544591Dermatitis, Atopic · China | 2 | Completed | Jul 10, 2023 | 93 |
| NCT04527718Healthy · United States | 1 | Completed | Aug 13, 2021 | 40 |
How it is read
Names in the registry
- “611”, 8 entries
- “Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)”, 1 entry
- “611 300 mg Q2W”, 1 entry
- “611 450 mg Q2W”, 1 entry
- “611 Q2W”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 6 studies
- Sinusitis, 2 studies
- Pulmonary Disease, Chronic Obstructive, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.